Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Net Cash Flow (2021 - 2026)

HeartSciences' Net Cash Flow history spans 6 years, with the latest figure at $1.4 million for Q1 2026.

  • For Q1 2026, Net Cash Flow rose 199.34% year-over-year to $1.4 million; the TTM value through Jan 2026 reached $800513.0, up 117.87%, while the annual FY2025 figure was -$4.7 million, 213.56% down from the prior year.
  • Net Cash Flow reached $1.4 million in Q1 2026 per HSCS's latest filing, up from -$841128.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $7.0 million in Q1 2024 to a low of -$1.5 million in Q2 2025.
  • Average Net Cash Flow over 5 years is $178038.6, with a median of -$475510.0 recorded in 2023.
  • The largest YoY upside for Net Cash Flow was 709.28% in 2024 against a maximum downside of 369.1% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$1.2 million in 2022, then surged by 60.26% to -$475510.0 in 2023, then soared by 39.51% to -$287658.0 in 2024, then crashed by 192.41% to -$841128.0 in 2025, then surged by 271.9% to $1.4 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Net Cash Flow are $1.4 million (Q1 2026), -$841128.0 (Q4 2025), and $1.7 million (Q3 2025).